Back to Search Results
 
Nehal Mehta Nehal Mehta
Chief, Section of Inflammation and Cardiometabolic Diseases (National Heart, Lung, and Blood Institute, NIH)
Clinical Professor of Medicine
Clinical Professor of Dermatology (Secondary)

Office Phone: 202-741-2233
Email: Email
Department: Medicine

Biography

Nehal Mehta moved in 2012 from the Perelman School of Medicine at the University of Pennsylvania (Penn) to the National Institutes of Health (NIH) as the inaugural Lasker Scholar, a joint program between the NIH and the Lasker Foundation. He is currently the Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute.

Dr. Mehta is board-certified in internal medicine, cardiovascular medicine, echocardiography and nuclear cardiology. He specializes in preventive cardiology and clinical research. To that end, Dr. Mehta founded the nation’s first inflammatory risk clinic within Preventive Cardiology in 2008 at Penn which focused on cardiovascular risk stratification in patients with psoriasis. Using his background in nuclear cardiology, Dr. Mehta utilized positron emission tomography (PET) to demonstrate that inflammatory conditions “age” the blood vessels earlier and that psoriasis was a systemic disease which affected more than just the skin. His contributions to the field led to the World Health Organization deeming psoriasis a systemic disease which should be screened for comorbid disease. Dr. Mehta clinically performs consultative general cardiology, Lipidology, coronary care unit service and also hospital rounds.

Training

Residency:
  • Residency in Internal Medicine, Hospital of University of Pennsylvania, 2002-2004
Fellowship:
  • Fellow in Cardiovascular Medicine, Hospital of the University of Pennsylvania, 2005-2007

Expertise

  • General Cardiology
  • Lipidology
  • Metabolic characterization
  • Image quantification

Research

Dr. Mehta has clinical and research interests in moving epidemiological observations into translational studies in humans studying how inflammation affects insulin resistance, the metabolic syndrome, lipoprotein function and atherosclerosis. He directs a section at the NIH which includes three arms: 1) imaging quantification of PET CT, PET MRI and coronary CT angiography; 2) lipid phenotyping including HDL functional studies and lipid particle number and size measurement using NMR; 3) a pre-clinical and in vitro laboratory program to understand endothelial cell biology in the context of inflammation.

Community Service

Dr. Mehta performs health screenings for patients with chronic diseases due to inflammation

Division

  • Cardiology

Publications

Takeshita J, Mohler ER, Krishnamoorthy P, Moore J, Rogers WT, Zhang L, Gelfand JM, Mehta NN. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc. 2014 Feb 28; 3(1).

Mehta N, Qamar A, Qu L, Qasim AN, Mehta NN, Reilly MP, Rader DJ. Differential association of plasma angiopoitin-like proteins 3 and 4 with lipid and metabolic traits. Arterioscler Thromb Vasc Biol. 2014 May; 34(5).

Mehta NN, Dagur PK, Rose SM, Naik HB, Stansky E, Doveikis J, Biancotto A, Playford MP, McCoy JP Jr. IL-17A production in human psoriatic blood and lesions by CD146+ T cells. J Invest Dermatol. 2014 July 24.

Subramanain S, Liu C, Aviv A, Ho JE, Courchesne P, Muntendam P, Larson MG, Cheng S, Wang TJ, Mehta NN, Levy D. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol. 2014 Jul 24.

Rose S, Dave’ J, Millo C, Naik HB, Siegel EL, Mehta NN. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Res Ther. 2014 Jul 30; 16(4):R161 [Epub ahead of print].

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None